FDA cleared Dexcom's Stelo Glucose Biosensor System as the first over-the-counter continuous glucose monitor for children, but the indication is for people age 2 and older who do not use insulin. [1]

The paper's June 14 brief said medical-device alerts need patient translation. FDA's June 12 diabetes pair is a translation exercise in miniature: one action moves monitoring into the home for a bounded pediatric group; the other approves a drug for a different disease stage under clinical constraints.

Stelo is not a pediatric free-for-all. FDA says the device is for children, including some with diabetes, who receive oral medication, and for people who want to understand how diet, exercise and lifestyle changes affect glucose. The wearable sensor pairs with a smartphone app, displays measurements and trends every 15 minutes, and each sensor lasts up to 15 days, though pediatric wear time may be shorter. [1]

The boundaries matter more than the gadget. Children should use Stelo under adult caregiver supervision. Users and caregivers should consult a health-care provider before making medication changes. FDA also says Stelo is not for people with problematic hypoglycemia because it is not designed to alert users to low blood sugar, and it is not for people on dialysis. [1]

On the drug side, FDA approved Tzield for pediatric patients age 8 to 17 who were recently diagnosed with stage 3 type 1 diabetes, to slow the loss of the body's own insulin production. [2] That is not the same population and not the same task.

FDA describes stage 3 type 1 diabetes as the symptomatic stage, when high blood sugar produces signs such as frequent urination, excessive thirst and fatigue, and the patient requires insulin therapy. Tzield's PROTECT study included 328 patients age 8 to 17 recently diagnosed with stage 3 disease and measured beta-cell function at 78 weeks using C-peptide. [2]

The safety boundary is also different. Tzield carries a boxed warning for serious life-threatening viral reactivation, including Epstein-Barr virus and cytomegalovirus. FDA says patients should be tested for active EBV and CMV infection before treatment, and lists cytokine release syndrome, allergic reactions and white-blood-cell reductions among safety concerns. [2]

X can make this into cure language. Gadget coverage can make it into child glucose-tech enthusiasm. The useful family version is narrower: Which child? Which device or drug? Which adult supervises? Which clinician changes medication? Which lab or infection screen comes first?

FDA gave two advances on one date. The service story is making sure no parent mistakes one boundary for the other.

-- KENJI NAKAMURA, Tokyo